Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Overview of attention for article published in Nature Medicine, August 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 102 news outlets
blogs: 8 blogs
twitter: 372 X users
facebook: 2 Facebook pages

reddit: 9 Redditors
video: 1 YouTube creator
bluesky: 86 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 86 Mendeley

So far, Altmetric has seen 411 X posts from 372 X users, with an upper bound of 5,146,083 followers.

Final AMPLIFY-201 results further evaluated lymph-node-targeted mutant KRAS peptide vaccination in pancreatic and colorectal cancer with minimal residual disease. A strategy to target cancer before overt recurrence. https://t.co/rzdw3b3NkR

RT @pashtoonkasi: 🆕🗞️Hot off the press! @NatureMedicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come w…

RT @Aiims1742: 3/10: More success with vaccines in localized #PancreaticCancer, this one an amphiphilic mutant KRAS targeted peptide vaccin…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 407 additional X posts.